Listed Pharmaceutical Companies See Stronger Sales Growth in Q2, Led by Mid-Sized Firms

[NEWSMP] According to Newsmp’s analysis of semiannual reports of listed pharmaceutical companies with fiscal years ending in November or December, sales at the 66 companies surveyed grew by an average of 9.0% in the second quarter, approaching double-digit growth. All figures are based on separate financial statements.

Of the 66 companies surveyed, nearly half, or 31, posted double-digit sales growth, suggesting a modest improvement in industry conditions. However, 14 companies reported year-on-year declines in sales, with five recording decreases of more than 10%.

By company size, large pharmaceutical companies with quarterly sales of KRW 100 billion or more posted average sales growth of 8.9%. Upper-mid-sized companies with sales between KRW 50 billion and KRW 100 billion recorded 10.4% growth, while lower-mid-sized companies with sales between KRW 25 billion and KRW 50 billion achieved 11.0%.

While mid-sized companies showed particularly strong performance and larger companies also delivered solid results, smaller companies with quarterly sales below KRW 25 billion posted average sales growth of just 1.4%.

Among individual companies, ST Pharm recorded the highest sales growth rate at 66.5%, while Hanmi Pharmaceutical also delivered robust growth of 47.3%.

Sam Chun Dang Pharm, Daehwa Pharmaceutical, Bukwang Pharmaceutical, and CMG Pharmaceutical all posted growth rates of more than 25%, approaching the 30% mark, while Sinil Pharmaceutical recorded growth of more than 20%.

Yuyu Pharma, Korean Drug, Dongkook Pharmaceutical, Ahn-Gook Pharmaceutical, Dong-A ST, Celltrion Pharm, JW Pharmaceutical, BC World Pharmaceutical, Sinsin Pharmaceutical, Kyongbo Pharmaceutical, and Kyungnam Pharm also posted sales growth exceeding 15%.

Hyundai Pharmaceutical, Dongwha Pharmaceutical, Optus Pharmaceutical, Cho-A Pharmaceutical, Boryung, Whan In Pharm, Korea Pharma, Withus Pharmaceutical, Chong Kun Dang Pharmaceutical, Dongsung Pharmaceutical, Yuhan Corporation, Kukje Pharma, and Daewoong Pharmaceutical also recorded double-digit sales growth.

In addition, Daihan Pharmaceutical, Ildong Pharmaceutical, Korea United Pharm, Handok, JW Shinyak, HanAll Biopharma, Myungmoon Pharm, Jinyang Pharm, Jeil Pharmaceutical, Sam-A Pharm, Shinpoong Pharmaceutical, KyungDong Pharmaceutical, Samjin Pharmaceutical, Daewon Pharmaceutical, Myung In Pharm, Il-Yang Pharmaceutical, Hana Pharm, and Samik Pharmaceutical all recorded sales growth of more than 5%. HK inno.N and DongKoo Bio&Pharma also posted modest year-on-year sales growth.

In contrast, Union Korea Pharm reported a 41.4% decline in sales, while DongKook Lifescience saw a 30.5% decline. GC Biopharma, Hwail Pharm, and Huons also saw sales decline by more than 10%.

Samsung Pharmaceutical, Korea Arlico Pharm, Samil Pharmaceutical, Reyon Pharmaceutical, Kwangdong Pharmaceutical, Seoul Pharmaceuticals, Yungjin Pharm, JW Life Science, and CKD Bio also reported year-on-year declines in sales.

In terms of quarterly sales, Yuhan Corporation topped KRW 600 billion, reaching KRW 614.0 billion, followed by Chong Kun Dang Pharmaceutical, Hanmi Pharmaceutical, and Daewoong Pharmaceutical, each with sales in the KRW 400 billion range.

GC Biopharma reported sales in the KRW 300 billion range, while Boryung, HK inno.N, Kwangdong Pharmaceutical, Dongkook Pharmaceutical, JW Pharmaceutical, and Dong-A ST each reported sales in the KRW 200 billion range.

Celltrion Pharm, Jeil Pharmaceutical, Ildong Pharmaceutical, Handok, Daewon Pharmaceutical, Huons, and Dongwha Pharmaceutical also reported quarterly sales of more than KRW 100 billion.

For the first half of the year, Yuhan Corporation was the only company to report sales exceeding KRW 1 trillion, reaching KRW 1.1237 trillion. Chong Kun Dang Pharmaceutical surpassed KRW 900 billion with sales of KRW 923.1 billion, approaching the KRW 1 trillion mark.

Daewoong Pharmaceutical followed with first-half sales of KRW 735.9 billion, while Hanmi Pharmaceutical posted KRW 692.2 billion, approaching the KRW 700 billion mark. GC Biopharma recorded KRW 602.2 billion, remaining above the KRW 600 billion mark.

HK inno.N remained above the KRW 500 billion mark with sales of KRW 525.9 billion, while Boryung also surpassed KRW 500 billion, reaching KRW 511.9 billion. Kwangdong Pharmaceutical remained in the KRW 400 billion range, while Dongkook Pharmaceutical and JW Pharmaceutical moved into the KRW 400 billion range.

Dong-A ST reported sales in the KRW 300 billion range, while Ildong Pharmaceutical, Jeil Pharmaceutical, Celltrion Pharm, Daewon Pharmaceutical, Handok, Huons, and Dongwha Pharmaceutical each reported first-half sales in the KRW 200 billion range.

Additionally, Ahn-Gook Pharmaceutical, ST Pharm, Korea United Pharm, Myung In Pharm, Samjin Pharmaceutical, Whan In Pharm, Kyongbo Pharmaceutical, Il-Yang Pharmaceutical, Yungjin Pharm, Hana Pharm, DongKoo Bio&Pharma, JW Life Science, Shinpoong Pharmaceutical, Daihan Pharmaceutical, Samil Pharmaceutical, and Hyundai Pharmaceutical each reported first-half sales exceeding KRW 100 billion.